For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Growth Hormone Secretagogues

Follistatin 344

Also known as: FS-344

Follistatin 344 is a recombinant form of the naturally-occurring glycoprotein (344-residue splice variant) that inhibits activin and myostatin signaling. Clinical validation exists ONLY through small AAV gene-therapy phase 1/2 trials in Becker muscular dystrophy; recombinant injectable protein sold on the grey market has no clinical evidence. NOT FDA-approved. WADA-prohibited (myostatin inhibitor) and banned in competitive sport.

Where to buy · live market data

Who's worth your money for Follistatin 344

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (88) of 1 scored sellers

$96.00/mg

$96.00 · 1mg

no COAs yet

Average price

$126.55/mg

Sellers

9

45-day trend

-5.9%

7 of 9 sellers have a current price· 3 stale hidden· 3 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch Follistatin 344

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About Follistatin 344

CAS

—

Molecular formula

—

Sequence

MVRARHQPGGLCLLLLLLCQFMEDRSAQAGNCWLRQAKNGRCQVLYKTELSKEECCSTGRLSTSWTEEDVNDNTLFKWMIFNGGAPNCIPCKETCENVDCGPGKKCRMNKKNKPRCVCAPDCSNITWKGPVCGLDGKTYRNECALLKARCKEQPELEVQYQGRCKKTCRDVFCPGSSTCVVDQTNNAYCVTCNRICPEPASSEQYLCGNDGVTYSSACHLRKATCLLGRSIGLAYEGKCIKAKSCEDIQCTGGKKCLWDFKVGRGRCSLCDELCPDSKSDEPVCASDNATYASECAMKEAACSSGVLLEVKHSGSCNSISEDTEEEEEDEDQDYSFPISSILEW

Typical dose range

100–200 mcg/day subcutaneous (research use; cycles of 10–30 days on, 3–4 weeks off)

Half-life

~90 minutes (recombinant injectable form); endogenous FST-315 isoform estimated ~10–15 hours

Research depth

12 citations indexed for Follistatin 344

All research on Follistatin 344 →

review · 2026

Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement.

review · 2026

Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives

Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes.

Study · 2026

Grip strength as a systems biomarker of aging: neuromuscular junction constraints and biomarker decoupling in gene therapy

Grip strength has emerged as one of the most robust predictors of mortality, disability and healthspan across populations.

review · 2026

Sarcopenia and Skeletal Muscle Dysfunction in Liver Cirrhosis: Clinical Perspectives of Myostatin Inhibition

Liver cirrhosis is frequently complicated by sarcopenia, a progressive and systemic loss of skeletal muscle mass and function that contributes substantially to increased morbidity, mortality, and healthcare utilisation.

review · 2026

Disruption of the Muscle-Brain Axis in Ageing: Role of Myokines in Sarcopenia and Neurodegeneration

This narrative review analyzes how myokines act as key links in communication between skeletal muscle and the brain, focusing on the impact of aging on this axis.

review · 2026

Myostatin Research: From Molecular Understanding to Clinical Translation for Musculoskeletal and Metabolic Disorders

Myostatin (Mstn), a well-characterized member of the transforming growth factor-β (TGF-β) superfamily, serves as a key negative regulator of skeletal muscle mass. Its overactivation is closely associated with the pathogenesis of various musculoskeletal and metabolic disorders.